-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Medical Crossfire: Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies

Sponsor: Lilly, Merck & Co., Inc., Pharmacyclics LLC, an AbbVie Company’s and Janssen Biotech, Inc.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Diseases, Therapies, Adverse Events, Biological Processes, Minimal Residual Disease
Friday, December 8, 2023: 7:00 AM-10:00 AM
Room 6B (San Diego Convention Center)
Chair:
Ian W. Flinn, MD, PhD, Sarah Cannon Research Institute and Tennessee Oncology
Disclosures:
Flinn: Pfizer: Research Funding; Pharmacyclics: Research Funding; Verastem: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; Genmab: Consultancy; InnoCare Pharma: Consultancy, Research Funding; Myeloid Therapeutics: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Secura Bio: Consultancy; Servier Pharmaceuticals: Consultancy; TG Therapeutics: Consultancy, Research Funding; Vincerx Pharma: Consultancy, Research Funding; Seagen: Research Funding; MorphoSys: Research Funding; Merck: Research Funding; Karyopharm: Research Funding; Juno: Consultancy, Research Funding; Kite, a Gilead Company: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Iksuda: Consultancy; Hutchison MediPharma: Consultancy; Great Point Partners: Consultancy; Gilead Sciences: Consultancy, Research Funding; Xencor: Consultancy; 2seventy bio: Research Funding; Agios: Research Funding; ArQule: Research Funding; Biopath: Research Funding; Bristol Myers Squibb: Research Funding; CALIBR: Research Funding; CALGB: Research Funding; Celgene: Research Funding; City of Hope National Medical Center: Research Funding; Constellation Pharmaceuticals: Research Funding; Curis: Research Funding; CTI Biopharma: Research Funding; Epizyme: Research Funding; Fate Therapeutics: Research Funding; Forma Therapeutics: Research Funding; Forty Seven: Research Funding; IGM Biosciences: Research Funding; Incyte: Research Funding; Infinity Pharmaceuticals: Research Funding; Loxo: Research Funding; Marker Therapeutics: Research Funding; Millennium Pharmaceuticals: Research Funding; Nurix: Research Funding; Portola Pharmaceuticals: Research Funding; Rhizen Pharmaceuticals: Research Funding; Roche: Research Funding; Step Pharma: Research Funding; Tessa Therapeutics: Research Funding; Trillium Therapeutics: Research Funding; BeiGene: Consultancy; Seattle Genetics: Research Funding; Triphase Research & Development Corp.: Research Funding; Genentech: Consultancy, Research Funding; Century Therapeutics: Consultancy; BeiGene: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; Acerta Pharma: Consultancy, Research Funding; Unum Therapeutics: Research Funding.
Speakers:
Catherine C. Coombs, MD, University of California Irvine , Paolo Strati, MD, The University of Texas MD Anderson Cancer Center , Michael Wang, MD, The University of Texas MD Anderson Cancer Center and Steven P. Treon, MD, PhD, FRCP, Dana-Farber Cancer Institute
Disclosures:
Coombs: AbbVie, Genentech, Beigene, AstraZeneca, Lilly, Octapharma: Consultancy. Strati: ALX Oncology: Research Funding; ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Sobi: Membership on an entity's Board of Directors or advisory committees, Research Funding; Astrazeneca Acerta: Membership on an entity's Board of Directors or advisory committees, Research Funding; Hutchinson MedoPharma: Consultancy; Kite Gilead: Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche Genentech: Consultancy. Wang: Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Genentech, Innocare, Janssen, Juno Therapeutics, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics, VelosBio: Research Funding. Treon: Abbvie/Pharmacyclics: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; BeiGene: Consultancy, Research Funding; Eli Lilly: Consultancy, Research Funding; Bristoll Myers Squibb: Consultancy, Research Funding.
Access Program Details

The rapid pace and sheer volume of basic science and therapeutic developments that continue to emerge in the field of BTK inhibitors creates practice and/or educational gaps, particularly for hematology-oncologists and oncology nurses who strive to deliver the best possible care to patients. This Medical Crossfire® will provide an ideal format for the lymphoma care team to participate in an open exchange of ideas and viewpoints fostered by a case-based agenda allowing them to review patient scenarios, reflect on how they might handle particular cases, integrate relevant evidence into real-world practice, and compare their patient care approaches with those of experts and peers. Faculty leading discussion of common clinical scenarios and solutions will discuss methods to best integrate the latest therapies into B-cell lymphoma treatment paradigms, address barriers to optimized integration of these novel agents, as well provide best practices for the management of adverse events.